ESR1 and neoplasm: Since imlunestrant exhibited superior Y537S ESR1 mutant protein degradation and enhanced suppression of tumor growth in the Y537S ESR1 mutant PDX model compared with fulvestrant, even with a fulvestrant dose considered above the clinically relevant therapeutic range (22), we hypothesized that imlunestrant impacts helix 12 differently than fulvestrant.